Lung Cancer

Women with lung cancer who ate more soy prediagnosis appear to survive longer than patients who ate fewer soy-based foods, according to a new Chinese study.

The faster one smokes a cigarette after waking in the morning, the higher the biologic exposure to an important tobacco-related carcinogen, according to a new study. Time to first cigarette, or TTFC, could be a useful marker of high lung cancer risk among smokers as a result.

In this interview, ahead of the AACR annual meeting, we speak with Dr. Julie Brahmer, of Johns Hopkins School of Medicine, who is giving a presentation on immunotherapy in lung cancer, and is one of the clinical investigators of the extensive phase I trial of the anti–PD-1 antibody nivolumab.

I see these tragedies unfold so often it has become routine for me now, yet don’t think that your life was less precious, that your death is less grievous, just because you killed yourself with cigarettes. It is not too late to change your future-listen to me!

Improving the selection criteria for lung cancer screening, which remains controversial, can improve the sensitivity of screening without losing specificity, and could help avoid additional deaths from lung cancer.

Based on revised data from a troubled phase II trial of the new drug bavituximab, Peregrine Pharmaceuticals is aiming to move the agent into phase III testing in non–small-cell lung cancer (NSCLC) by the end of 2013.

Most Americans are aware that technical experts from Consumer Reports magazine consistently rank televisions and automobiles manufactured by Japanese companies higher than their US counterparts, but I believe that neither Consumer Reports nor US physicians understand how much better lung cancer treatment results are in Japan.

Increased levels of human epidermal growth factor receptor (HER) may be the key to chemotherapy resistance in non–small-cell lung cancer (NSCLC), according to a new study.

The combination of whole-brain radiation therapy and the EGFR inhibitor erlotinib showed a promising response rate and was well tolerated in a new phase II trial of patients with brain metastases from non-small-cell lung cancer.

Women have caught up to men with regard to the risk of death from cigarette smoking, according to analyses of three study cohorts spanning multiple decades and hundreds of thousands of individuals.

Participants in the National Lung Screening Trial did not change their perceptions of risk for lung cancer and smoking-related disease between prescreening enrollment and a 1-year follow-up visit, regardless of the result of the screening test.

Lung cancer patients who take beta-adrenergic receptor antagonists (beta-blockers) may survive longer and have a lower rate of tumor spread, according to a new study.

Expression of certain immune markers in tumor and surrounding cells can help predict probabilities of recurrence in patients with stage I lung adenocarcinoma, according to new researcher.

The clinical management of malignant mesothelioma may ultimately be transformed by the elucidation of novel biomarkers that can predict the evolution of disease and guide the development of targeted therapies. However, despite relevant advances, more basic research is urgently required to support the development of therapies applicable to the patients for whom surgical resection is not an option.

Significant advances have been made in our understanding of the factors affecting the prognosis of malignant mesothelioma, and a number of biomarkers appear promising. However, at present it may be more fruitful to better define and characterize clinical factors that are well recognized as significantly impacting patient survival.

Here we examine recent advances in the knowledge of this severe and heterogeneous malignancy, and we analyze the clinical significance of prognostic factors.

Initiating discussions about end-of-life care with patients with incurable cancers early in their disease was associated with a decrease in late-stage aggressive cancer treatments such as chemotherapy or acute care, and with an increase in the use of hospice care at the end of life.

In the first chemoprevention trial with a non-FDA-approved, oral, small-molecule-targeted agent, enzastaurin did not meet a primary endpoint but showed reasonable tolerability and some success in subgroup analyses.

Obese lung cancer patients undergoing lobectomy spend more time in the operating room than patients with lower body mass index, according to a new study. BMI was not associated with 30-day mortality or increased length of hospital stay.

Researchers have found a novel cellular mechanism that determines resistance to various targeted cancer therapies and several different cancers. The gene may be a key biomarker that could predict responses and provide better strategies to treat drug-resistant cancers.

Genotyping, sometimes referred to as molecular fingerprinting, must be distinguished from genetic testing. Genotyping is done to tumor samples and tests genes in the malignancy only.

This second article in our two-part series on targeted therapies in solid tumors covers the emergence of targeted therapies for the treatment of two common malignancies: lung cancer and breast cancer.

A phase II trial and a pooled analysis with another study found no benefit to adding carboplatin to pemetrexed versus pemetrexed alone in previously treated patients with advanced non-small-cell lung cancer (NSCLC).

A significant portion of patients with incurable lung cancer believe that palliative radiation therapy will cure the disease or at least help them live longer, according to a new study. Only about one-third of patients acknowledged that the treatment was not at all likely to cure their cancer.

The rarity and heterogeneity of these tumors limits research and obviates the possibility of large randomized clinical trials. Surgery remains the mainstay of treatment, but often radiotherapy and/or chemotherapy is required. The role of neoadjuvant therapy is evolving. In the not too distant future, new therapies tailored to the molecular profile of the tumor will be available.